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EDITORIALAs an emerging strategy of regenerative medicine, stem cell
transplantation therapy has provided an exciting possibility
for the treatments of many devastating diseases, including
ischemic heart and brain disorders. For the clinical efficacy
and efficiency to be fulfilled, however, a number of issues
are still to be resolved in the potential cell-based therapy.
The poor survival of transplanted cells (often 70%–90%
death in a few days after transplantation) is one of the
most critical dilemmas that have been seriously and specif-
ically addressed in our recent investigations.1,2 Our article
recently published in this Journal, titled ‘‘Transplantation
of Hypoxia-Preconditioned Mesenchymal Stem Cells Im-
proves Infarcted Heart Function via Enhanced Survival of
Implanted Cells and Angiogenesis,’’ demonstrated a mark-
edly enhanced cell survival in the ischemic heart and func-
tional benefits achieved by the ‘‘hypoxic preconditioning’’
of stem cells before transplantation.2 The letter from Haider
and associates advocates the idea of preconditioning trans-
planted cells and has provided new experimental evidence
for this novel approach.
Hypoxic or ischemic preconditioning is the principle by
which a brief, sublethal exposure of cells, tissues, or animals
to hypoxia or ischemia induces a cytoprotective phenotype
on subsequent potentially lethal challenges. The precondi-
tioning stimulus may be accomplished by many means. For
example, we have successfully preconditioned mesenchymal
stem cells with 24-hour 0.5% oxygen before transplantation
into the ischemic heart and embryonic stem cells before
transplantation into the ischemic brain. Haider and associates
discuss the use of an alternate preconditioning protocol, using
short bursts of ischemia and reperfusion, which they similarly
find effective for enhancing cell survival. These and other
studies illustrate that there could be different means to acti-
vate the cytoprotective pathways in the different cells or
even in the same type of cells for transplantation therapy.
Following our published work mentioned above, we have
been exploring the use of small molecule inhibitors of the
oxygen-dependent hydroxylase enzymes as another means
to activate preconditioning pathways. Proline and aspargine
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ate target proteins to effect signaling changes. In this way,
environmental oxygen concentration controls the signaling
pattern of the oxygen-dependent enzymes. Our very recent
data show that pharmacologic inhibition of prolyl hydroxy-
lase enzymes mimics the effect of hypoxic or ischemic pre-
conditioning. We3 demonstrate that the prolyl hydroxylase
competitive inhibitor dimethyl-oxylyglycine activates pro-
tective pathways in mesenchymal stem cells, reducing cell
death by the serum deprivation insult. This protection is con-
current with hypoxia-inducible factor 1a activation and is
blocked by inhibition of phosphoinositide 3-kinase and
downstreamAkt activation. Oxygen-dependent hydroxylase
inhibitor preconditioning may therefore be another strategy
to enhance the survival of cells before transplantation.
An important ongoing challenge in this field is the identi-
fication of downstreammediators of hypoxic preconditioning
protection. Hypoxia inducible factor is the most studied tran-
scription factor activated by hypoxia; however, it does not
account for all the changes in gene expression that occur un-
der preconditioning. Using a microarray technique, Frank
Sharp’s group (Xu and associates4) has identified thousands
of genes that are upregulated or downregulated by hypoxic
preconditioning in the brain. Haider and associates discuss
the potential for participation of hypoxia-regulated micro-
RNAs in the mechanism of preconditioning-enhanced cell
survival. MicroRNAs are an important posttranscriptional/
pretranslational level of control of gene expression and can
mediate the degradation of messenger RNA or suppression
of protein translation. Inasmuch as a number of gene tran-
scripts are downregulated by hypoxia, understanding the
role of microRNAs in this process will be an interesting con-
tribution to the field. Ultimately, understanding the cellular
and molecular mechanisms that mediate the increased capac-
ity for cell survival by preconditioning will help to identify
new, more directed therapeutic targets for facilitating cell
transplantation–based regenerative medicine.
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